Revenue rose 25.3 percent to 896 million dollars (715). This figure compares with the Factset analyst consensus of 906 million dollars.
Operating profit amounted to 180 million dollars (188), missing the expected 187 million dollars. The operating margin stood at 20.1 percent (26.3).
Net profit for the period was 53 million dollars (195).
The company is reiterating its full-year guidance for revenue of 4,065-4,395 million dollars and an operating profit of 900-1,400 million dollars.
| Genmab, MUSD | Q1-2026 | Consensus | Change vs Consensus | Q1-2025 | Change |
| Net sales | 896 | 906 | -1.1% | 715 | 25.3% |
| Operating profit | 180 | 187 | -3.7% | 188 | -4.3% |
| Operating margin | 20.1% | 20.6% | 26.3% | ||
| Net profit | 53 | 195 | -72.8% |
